CNS Pharmaceuticals, Inc. CNSP
"we," "us," or "our") is a biotechnology company focused on developing innovative therapies for serious
diseases in neurology and oncology. Together, these therapeutic areas represent hundreds of billions of dollars in annual global pharmaceutical
spending, encompass some of the most prevalent and difficult to treat diseases affecting humanity, and are characterized by significant
unmet medical need. Significant progress has been made in the biological and molecular understanding of these diseases, enabling a shift
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| R&D | $9.8M | $9.3M | $14.1M | $9.3M | $9.8M | $5.1M | $1.9M | $21.3K | — |
| SG&A | $6.2M | $5.6M | $4.8M | $6.0M | $4.7M | $4.4M | $2.0M | $860.5K | — |
| Total operating expenses | $16.0M | $14.9M | $18.9M | $15.3M | $14.5M | $9.5M | $3.8M | $881.8K | — |
| Operating income | -$16.0M | -$14.9M | -$18.9M | -$15.3M | -$14.5M | -$9.5M | -$3.8M | -$881.8K | — |
| Interest expense | $15.2K | $16.1K | $13.8K | $7.0K | $9.3K | $3.3K | $26.2K | $28.6K | — |
| Pre-tax income | -$16.0K | -$14.9K | -$18.9K | -$15.3M | -$14.5M | -$9.5M | -$3.9M | -$7.4M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$16.0K | -$14.9K | -$18.9K | -$15.3M | -$14.5M | -$9.5M | -$3.9M | -$7.4M | — |
| EPS, basic | -35.75 | -466.89 | -12,509.11 | -11.22 | -16.50 | — | — | — | — |
| EPS, diluted | -35.75 | -466.89 | -12,509.11 | -11.22 | -16.50 | -0.57 | -0.28 | -0.70 | — |
| Shares, diluted (wtd. avg.) | $443.4K | $31.8K | $1.5K | $1.4M | $878.4K | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.2M | $6.5M | $548.7K | $10.1M | $5.0M | $14.0M | $7.2M | $555.1K | $110.5K |
| Total current assets | $8.1M | $8.7M | $1.6M | $12.6M | $7.5M | $15.5M | $7.9M | $588.1K | — |
| Property, plant and equipment | $17.7K | $6.0K | $4.9K | $5.7K | $16.1K | $23.4K | $18.2K | $0 | — |
| Total assets | $8.6M | $8.7M | $1.7M | $13.1M | $8.8M | $15.9M | $7.9M | $683.3K | — |
| Accounts payable | $3.8M | $2.2M | $5.8M | $4.5M | $2.0M | $946.3K | $243.7K | $128.1K | — |
| Short-term debt | — | — | — | $449.9K | $426.0K | $482.4K | — | — | — |
| Total current liabilities | $4.1M | $2.5M | $6.1M | $4.9M | $2.6M | $1.9M | $311.0K | $1.2M | — |
| Total liabilities | $4.1M | $2.5M | $6.1M | $4.9M | $2.6M | $1.9M | $311.0K | $1.2M | — |
| Retained earnings | -$100.3M | -$84.4M | -$69.6M | -$50.7M | -$35.4M | -$20.9M | -$11.5M | -$7.6M | — |
| Total equity | $4.5M | $6.2M | -$4.4M | $8.1M | $6.2M | $13.9M | $7.6M | -$549.3K | -$58.5K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.8M | -$17.1M | -$14.1M | -$10.6M | -$13.5M | -$7.3M | -$3.6M | -$716.4K | — |
| Depreciation and amortisation | $3.9K | $3.3K | $4.1K | $11.8K | $13.1K | $11.1K | $2.0K | $0 | — |
| Stock-based compensation | $187.7K | $839.0K | $1.0M | $1.2M | $1.7M | $1.3M | $477.1K | $110.2K | — |
| Capital expenditure | $18.2K | $4.2K | $3.9K | $4.4K | $5.7K | $17.9K | $20.1K | $0 | — |
| Investing cash flow | -$18.2K | -$4.2K | -$3.9K | -$4.4K | -$5.7K | -$17.9K | -$20.1K | $0 | — |
| Financing cash flow | $14.6M | $23.0M | $4.6M | $15.6M | $4.5M | $14.1M | $10.3M | $1.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001683168-26-006660.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |